Nanoparticles have experienced increasing demand in recent years in biopharmaceutical formulations, owing to their utility for both enhancing the characteristics of drugs and acting as drug delivery systems.
At present, a majority of CDMOs outsource their nanoparticle supply chain, however in house manufacturing of nanoparticles at CDMOs is anticipated to create new market opportunities aligning to biopharma's needs for these molecules.
Download our latest white paper to learn how partnering with a CDMO experienced in nanoparticle formulation and scale-up can help identify and overcome challenges to maximize the potential for a drug programs success.
